---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-001754"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2023-03-24T23:59:59+00:00"
generated_at: "2026-06-17T16:24:33.127829+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Nasdaq notified SBFM on March 24, 2023, of bid price non-compliance under Rule 5550(a)(2).
- Closing bid price below $1.00 for 30 consecutive trading days triggered the deficiency.
- Company has 180 calendar days until September 20, 2023, to regain compliance.
- To cure, bid price must close at or above $1.00 for at least 10 consecutive business days.
- If not cured, SBFM may qualify for an additional 180-day period if other listing standards are met.

## SEC filing metadata
- accession: 0001683168-23-001754
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2023-03-24T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316823001754/0001683168-23-001754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316823001754/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-001754
- JSON: https://secwatch.observer/filing/0001683168-23-001754.json
- Plain text: https://secwatch.observer/filing/0001683168-23-001754.txt

## Key facts
- Listing & Compliance Notices
  Sunshine Biopharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: March 24, 2023, Sunshine Biopharma, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no immed
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316823001754/0001683168-23-001754-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.